Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient

Pediatric Hematology and Oncology

Volumn 24, Issue 6, 2007, Pages 437-445

  Ritzmo, Carina ^a   Söderhäll, Stefan ^b   Karlén, Jonas ^b   Nygren, Helen ^a   Eksborg, Staffan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Children; Doxorubicin; Etoposide; Obesity; Pharmacokinetics

Indexed keywords

DOXORUBICIN; DOXORUBICINOL; ETOPOSIDE; PREDNISOLONE; VINCRISTINE;

ARTICLE; BODY MASS; BODY SURFACE; DRUG CLEARANCE; DRUG DOSE REDUCTION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HODGKIN DISEASE; HUMAN; MORBIDITY; OBESITY; REMISSION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BODY SURFACE AREA; DOXORUBICIN; ETOPOSIDE; HODGKIN DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; OBESITY, MORBID; REMISSION INDUCTION;

EID: 34548119532     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010701451343     Document Type: Article

References (26)

1. Baker SD, Grochow LB, Donehower RC. Should anticancer drug doses be adjusted in the obese patient? J Natl Cancer Inst. 1995;87:333-334.
2. Poikonen P, Blomqvist C, Joensuu H. Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol. 2001;40:67-71.
3. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999;88:1-7.
4. Cheymol G. Clinical pharmacokinetics of drugs in obesity: an update. Clin Pharmacokinet. 1993;25:103-114.
5. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39:215-231.
6. Graubner UB, Schmidt P, Nathrath S, et al. Maligne lymphoma im kindesalter. Tumorzentrum München; c2006 [cited 2006 Nov 16]. Available from: http://www.krebsinfo.de/ki/empfehlung/lymphome/
7. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
8. Palm C, Björk O, Björkholm M, Eksborg S. Quantification of doxorubicin in plasma: a comparative study of capillary and venous blood sampling. Anti-Cancer Drugs. 2001;12:859-864.
9. Eksborg S, Söderhäll S, Frostvik-Stolt M, Lindberg A, Liliemark E. Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children. Anti-Cancer Drugs. 2000;11:237-241.
10. Eksborg S. Anthracycline pharmacokinetics: limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). Acta Oncol. 1990;29:339-342.
11. Eksborg S, Palm C, Björk O. A comparative pharmacokinetic study of doxorubicin and 4′-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure. Anti-Cancer Drugs. 2000;11:129-136.
12. Fleming RA, Eldridge RM, Johnson CE, Stewart CF. Disposition of high-dose methotrexate in an obese cancer patient. Cancer. 1991;68:1247-1250.
13. Cox J, Penn N, Masood M, Hancock AK, Parker D. Drug overdose: a hidden hazard of obesity. J R Soc Med. 1987;80:708-709.
14. Rodvold KA, Rushing DA, Tewksbury DA-1327. Doxorubicin clearance in the obese. J Clin Oncol. 1988;6:1321.
15. Eksborg S, Hardell L, Bengtsson NO, Sjödin M, Elfsson B. Epirubicin as a single agent therapy for the treatment of breast cancer: a pharmacokinetic and clinical study. Med Oncol Tumor Pharmacother. 1992;9:75-80.
16. Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ. Obesity in pediatric oncology. Pediatr Blood Cancer. 2005;45:881-891.
17. Navarro WH. Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant. 2003;31:961-966.
18. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267-1273.
19. Eksborg S, Strandler HS, Edsmyr F, Näslund I, Tahvanainen P. Pharmacokinetic study of i.v. infusions of adriamycin. Eur J Clin Pharmacol. 1985;28:205-212.
20. Frost BM, Eksborg S, Björk O, et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol. 2002;38:329-337.
21. Palle J, Frost BM, Peterson C, et al. Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs. 2006;17:385-392.
22. Bachur NR, Steele M, Meriwether WD, Hildebrand RC. Cellular pharmocodynamics of several anthrocycline antibiotics. J Med Chem. 1976;19:651-654.
23. Itoh K, Sasaki Y, Fujii H, et al. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. Clin Cancer Res. 2000;6:4082-4090.
24. Boos J, Real E, Schulze-Westhof E, et al. Investigation of the variability of etoposide pharmacokinetics in children. Int J Clin Pharmacol Ther Toxicol. 1992;30:495-497.
25. Palle J, Frost BM, Gustafsson G, et al. Etoposide pharmacokinetics in children treated for acute myeloid leukemia. Anticancer Drugs. 2006;17:1087-1094.
26. Boos J, Krumpelmann S, Schulze-Westhoff P, et al. Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? J Clin Oncol. 1995;13:2954-2960.